Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Giovanni Sotgiu and Rosella Centis.
Giovanni Sotgiu
Connection Strength
3.970
Rosella Centis
  1. Understanding the multidrug-resistant tuberculosis epidemic in China. Int J Tuberc Lung Dis. 2017 09 01; 21(9):955.
    View in: PubMed
    Score: 0.366
  2. Tuberculosis and COVID-19, the new cursed duet: what differs between Brazil and Europe? J Bras Pneumol. 2021; 47(2):e20210044.
    View in: PubMed
    Score: 0.236
  3. Delamanid: does it have a role in tuberculosis treatment? Lancet Respir Med. 2019 03; 7(3):193-195.
    View in: PubMed
    Score: 0.201
  4. Migration, TB control and elimination: Whom to screen and treat. Pulmonology. 2018 Mar - Apr; 24(2):99-105.
    View in: PubMed
    Score: 0.187
  5. Breaking the barriers: Migrants and tuberculosis. Presse Med. 2017 Mar; 46(2 Pt 2):e5-e11.
    View in: PubMed
    Score: 0.177
  6. Management of extensively drug-resistant tuberculosis. Lancet Respir Med. 2017 04; 5(4):237-239.
    View in: PubMed
    Score: 0.175
  7. Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence. Eur Respir J. 2013 Jul; 42(1):288-90.
    View in: PubMed
    Score: 0.137
  8. COVID-19 and tuberculosis-threats and opportunities. Int J Tuberc Lung Dis. 2020 08 01; 24(8):757-760.
    View in: PubMed
    Score: 0.112
  9. Development of a standardised tool to survey MDR-/XDR-TB case management in Europe. Eur Respir J. 2010 Jul; 36(1):208-11.
    View in: PubMed
    Score: 0.111
  10. Recent evidence on delamanid use for rifampicin-resistant tuberculosis. J Thorac Dis. 2019 Mar; 11(Suppl 3):S457-S460.
    View in: PubMed
    Score: 0.101
  11. Tuberculosis elimination: a dream or a reality? The case of Oman. Eur Respir J. 2018 01; 51(1).
    View in: PubMed
    Score: 0.094
  12. Rifabutin: Is it useful in the treatment of multidrug-resistant tuberculosis? Int J Infect Dis. 2017 12; 65:133-134.
    View in: PubMed
    Score: 0.093
  13. Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review. J Thorac Dis. 2017 Jul; 9(7):2093-2101.
    View in: PubMed
    Score: 0.090
  14. A new free-cost e-service supporting clinicians to manage their difficult-to-treat tuberculosis cases: The European Respiratory Society-World Health Organization tuberculosis Consilium. Indian J Med Res. 2017 03; 145(3):261-263.
    View in: PubMed
    Score: 0.088
  15. Gauging the impact of the COVID-19 pandemic on tuberculosis services: a global study. Eur Respir J. 2021 11; 58(5).
    View in: PubMed
    Score: 0.061
  16. Time course of exercise capacity in patients recovering from COVID-19-associated pneumonia. J Bras Pneumol. 2021; 47(4):e20210076.
    View in: PubMed
    Score: 0.060
  17. The Role of Blood Gas Analysis in the Post-Acute Phase of COVID-19 Pneumonia. Arch Bronconeumol (Engl Ed). 2021 Jun 17.
    View in: PubMed
    Score: 0.059
  18. Tuberculosis, COVID-19 and hospital admission: Consensus on pros and cons based on a review of the evidence. Pulmonology. 2021 May-Jun; 27(3):248-256.
    View in: PubMed
    Score: 0.058
  19. Tuberculosis and COVID-19 interaction: A review of biological, clinical and public health effects. Pulmonology. 2021 Mar-Apr; 27(2):151-165.
    View in: PubMed
    Score: 0.058
  20. Functional impairment during post-acute COVID-19 phase: Preliminary finding in 56 patients. Pulmonology. 2021 Sep-Oct; 27(5):452-455.
    View in: PubMed
    Score: 0.058
  21. Coronavirus Disease-19: An Interim Evidence Synthesis of the World Association for Infectious Diseases and Immunological Disorders (Waidid). Front Med (Lausanne). 2020; 7:572485.
    View in: PubMed
    Score: 0.057
  22. Epidemic and pandemic viral infections: impact on tuberculosis and the lung: A consensus by the World Association for Infectious Diseases and Immunological Disorders (WAidid), Global Tuberculosis Network (GTN), and members of the European Society of Clinical Microbiology and Infectious Diseases Study Group for Mycobacterial Infections (ESGMYC). Eur Respir J. 2020 10; 56(4).
    View in: PubMed
    Score: 0.057
  23. Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January-April 2020. Emerg Infect Dis. 2020 11; 26(11):2709-2712.
    View in: PubMed
    Score: 0.056
  24. Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. Eur Respir J. 2020 07; 56(1).
    View in: PubMed
    Score: 0.056
  25. Tuberculosis, COVID-19 and migrants: Preliminary analysis of deaths occurring in 69 patients from two cohorts. Pulmonology. 2020 Jul - Aug; 26(4):233-240.
    View in: PubMed
    Score: 0.055
  26. Effectiveness of pulmonary rehabilitation in severe asthma: a retrospective data analysis. J Asthma. 2020 12; 57(12):1365-1371.
    View in: PubMed
    Score: 0.052
  27. Reducing tuberculosis transmission: a consensus document from the World Health Organization Regional Office for Europe. Eur Respir J. 2019 06; 53(6).
    View in: PubMed
    Score: 0.052
  28. International collaboration among medical societies is an effective way to boost Latin American production of articles on tuberculosis. J Bras Pneumol. 2019 Apr 25; 45(2):e20180420.
    View in: PubMed
    Score: 0.051
  29. Pulmonary rehabilitation is effective in patients with tuberculosis pulmonary sequelae. Eur Respir J. 2019 03; 53(3).
    View in: PubMed
    Score: 0.051
  30. Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review. Eur Respir J. 2018 07; 52(1).
    View in: PubMed
    Score: 0.048
  31. ERS/ECDC Statement: European Union standards for tuberculosis care, 2017 update. Eur Respir J. 2018 05; 51(5).
    View in: PubMed
    Score: 0.048
  32. Multi and extensively drug-resistant pulmonary tuberculosis: advances in diagnosis and management. Curr Opin Pulm Med. 2018 05; 24(3):244-252.
    View in: PubMed
    Score: 0.048
  33. Eliminating tuberculosis in Latin America: making it the point. J Bras Pneumol. 2018 04; 44(2):73-76.
    View in: PubMed
    Score: 0.048
  34. Renal Fanconi syndrome with meropenem-containing regimen in drug-resistant tuberculosis. Eur Respir J. 2018 03; 51(3).
    View in: PubMed
    Score: 0.048
  35. Eligibility for the shorter regimen for multidrug-resistant tuberculosis in Mexico. Eur Respir J. 2018 03; 51(3).
    View in: PubMed
    Score: 0.048
  36. Point of care diagnostics for tuberculosis. Pulmonology. 2018 Mar - Apr; 24(2):73-85.
    View in: PubMed
    Score: 0.047
  37. Diagnostic performances of the Xpert MTB/RIF in Brazil. Respir Med. 2018 01; 134:12-15.
    View in: PubMed
    Score: 0.046
  38. Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence. Eur Respir J. 2017 11; 50(5).
    View in: PubMed
    Score: 0.046
  39. Children under 5 years are at risk for tuberculosis after occasional contact with highly contagious patients: outbreak from a smear-positive healthcare worker. Eur Respir J. 2017 11; 50(5).
    View in: PubMed
    Score: 0.046
  40. Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis. Emerg Infect Dis. 2017 10; 23(10).
    View in: PubMed
    Score: 0.046
  41. Current use and acceptability of novel diagnostic tests for active tuberculosis: a worldwide survey. J Bras Pneumol. 2017 Sep-Oct; 43(5):380-392.
    View in: PubMed
    Score: 0.046
  42. Cross-border collaboration for improved tuberculosis prevention and care: policies, tools and experiences. Int J Tuberc Lung Dis. 2017 07 01; 21(7):727-736.
    View in: PubMed
    Score: 0.045
  43. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. Eur Respir J. 2017 05; 49(5).
    View in: PubMed
    Score: 0.045
  44. Resistance profile of drugs composing the "shorter" regimen for multidrug-resistant tuberculosis in Brazil, 2000-2015. Eur Respir J. 2017 04; 49(4).
    View in: PubMed
    Score: 0.044
  45. Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil. Eur Respir J. 2017 03; 49(3).
    View in: PubMed
    Score: 0.044
  46. Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline. Eur Respir J. 2017 03; 49(3).
    View in: PubMed
    Score: 0.044
  47. Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review. Int J Mol Sci. 2017 Feb 07; 18(2).
    View in: PubMed
    Score: 0.044
  48. Diabetes is Associated with Severe Adverse Events in Multidrug-Resistant Tuberculosis. Arch Bronconeumol. 2017 May; 53(5):245-250.
    View in: PubMed
    Score: 0.044
  49. Comparison of bacteriological conversion and treatment outcomes among MDR-TB patients with and without diabetes in Mexico: Preliminary data. Rev Port Pneumol (2006). 2017 Jan - Feb; 23(1):27-30.
    View in: PubMed
    Score: 0.044
  50. Is there a rationale for pulmonary rehabilitation following successful chemotherapy for tuberculosis? J Bras Pneumol. 2016 Sep-Oct; 42(5):374-385.
    View in: PubMed
    Score: 0.043
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.